XORTX delays renal treatment acquisition to March 31, 2026

XORTX Therapeutics Inc. has pushed back the completion date for its acquisition of a key renal treatment programme. The deal, first announced on today's date, now has a new deadline of March 31, 2026. Shareholders will also meet later in the month to discuss company matters.

The company initially agreed to buy the Renal Anti-Fibrotic Therapeutic Program (VB4-P5) from Vectus Biosystems Limited in a binding term sheet on October 17, 2025. The original closing date of January 13, 2026 was later extended, with an update issued on February 4, 2026. Regulatory approvals, including from the ASX, remain pending.

The extension gives both parties more time to finalise the transfer of intellectual property. Completion still depends on signing closing documents, meeting stock exchange rules, and complying with securities laws.

XORTX has also set its Annual and Special Meeting of Shareholders for March 24, 2026. Only those recorded as shareholders on February 20, 2026 will be eligible to vote at the event.

The new March 31 deadline allows further preparation for the acquisition's final steps. Shareholders will gather days earlier to address company business. The outcome of the deal hinges on regulatory clearance and legal compliance.